Compare CPAC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | JANX |
|---|---|---|
| Founded | 1949 | 2017 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.5M | 790.3M |
| IPO Year | 2003 | 2021 |
| Metric | CPAC | JANX |
|---|---|---|
| Price | $10.33 | $13.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $12.90 | ★ $53.60 |
| AVG Volume (30 Days) | 15.0K | ★ 834.3K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $4.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.10 | $12.12 |
| 52 Week High | $11.50 | $35.34 |
| Indicator | CPAC | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 44.13 |
| Support Level | $10.25 | $13.12 |
| Resistance Level | $11.37 | $13.79 |
| Average True Range (ATR) | 0.32 | 0.50 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 75.63 | 7.04 |
Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.